Demographic/characteristic | All enrolled patients (N = 250) |
---|---|
Age, y, mean (SD) | 60.2 (9.4) |
Male, n (%) | 169 (67.6) |
Type 2 diabetes,a n (%) | 188 (75.2) |
≥1 Relevant ophthalmic condition,b n (%) | 91 (36.4) |
Time since diagnosis, y, mean (SD) | 1.7 (2.6) |
Treated eye,c n | 91 |
Right only, n (%) | 17 (18.7) |
Left only, n (%) | 13 (14.3) |
Both, n (%) | 61 (67.0) |
Prior medications for DME, n | |
DEX | 84 |
Dexamethasone (systemic) | 6 |
Bevacizumab | 5 |
Ranibizumab | 4 |
Treated eye, n | 84 |
Right only, n (%) | 35 (41.7) |
Left only, n (%) | 45 (53.6) |
Both, n (%) | 4 (4.8) |
Concomitant medications for diabetes, n (%) | |
Metformin | 114 (45.6) |
Glimepiride | 76 (30.4) |
Concomitant medications for cardiovascular conditions, n (%) | |
Telmisartan | 55 (22.0) |
Atorvastatin | 32 (12.8) |
Blood and blood-forming agents | 44 (17.6) |
Last prior DEX dose to study entry dose, d | |
n | 80 |
Mean (SD) | 199.4 (156.0) |
Min, max | 0, 891 |